866-997-4948(US-Canada Toll Free)

Parkinson’s Disease Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Apr 2018

Category :

Therapeutic Area

No. of Pages : 211 Pages

Parkinson’s Disease Therapeutics Market - Overview

This report on Parkinson’s disease therapeutics market studies the current as well as future prospects of the market globally. Stakeholders of the market include companies and intermediaries engaged in the manufacturing, commercialization, providing therapeutic drugs for treatment of Parkinson’s disease, as well as new entrants planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global Parkinson’s disease therapeutics market with respect to the leading market segments based on drug class, route of administration, distribution channel, and geography.

The global Parkinson’s disease therapeutics market is divided into four segments on the basis of drug class, route of administration, distribution channel, and geography. Based on drug class, the market has been further segmented into Levodopa combination, dopamine agonists, MAO-B Inhibitors, COMT Inhibitors, and others. In terms of route of administration, the market has been classified into oral, transdermal, subcutaneous, intestinal infusion, and others. The Parkinson’s disease therapeutics market has also been studied from the point of distribution channel, based on which the market has been bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy.

Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of Parkinson’s disease. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment have been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR) percentage for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.

The market overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the Parkinson’s disease therapeutics market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global Parkinson’s disease therapeutics market.

Geographically, Parkinson’s disease therapeutics market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2015 to 2025, along with their respective CAGR for the forecast period from 2017 to 2025, considering 2016 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thus presenting a thorough examination of the overall competitive scenario of the global Parkinson’s disease therapeutics market.

Major players operating in the global Parkinson’s disease therapeutics market are AbbVie Inc., Novartis AG, F. Hoffmann-La Roche AG, Teva Pharmaceutical Industries Ltd., and UCB Inc, which exhibit the widest geographical outreach. Other prominent players operating in the global market include STADA Arzneimittel AG, GlaxoSmithKline plc, Valeant Pharmaceuticals International, Inc., Merck & Co., Inc., and Impax Laboratories Inc.

The global Parkinson’s disease therapeutics market is segmented as follows:

By Drug Class

  • Levodopa Combination
  • Dopamine Agonists
  • MAO-B Inhibitors
  • COMT Inhibitors
  • Others

By Route of Administration

  • Oral
  • Transdermal
  • Subcutaneous
  • Intestinal Infusion
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America (LATAM)
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

Chapter 1 Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2 Assumptions and Research Methodology

Chapter 3 Executive Summary: Global Parkinson’s Disease Therapeutics Market

Chapter 4 Market Overview
4.1. Introduction
4.2. Key Industry Developments

Chapter 5 Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
5.5. Global Parkinson’s Disease Therapeutics Market Outlook
5.6. Global Prevalence of Parkinson’s Disease
5.7. Pipeline Analysis

Chapter 6 Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
6.3.1. Levodopa Combination
6.3.2. Dopamine Agonists
6.3.3. MAO-B Inhibitors
6.3.4. COMT Inhibitors
6.3.5. Others
6.4. Market Attractiveness Analysis, by Drug Class

Chapter 7 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Route of Administration
7.1. Key Findings
7.2. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
7.2.1. Oral
7.2.2. Transdermal
7.2.3. Subcutaneous
7.2.4. Intestinal Infusion
7.2.5. Others
7.3. Market Attractiveness Analysis, by Route of Administration
7.4. Key Trends

Chapter 8 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel

Chapter 9 Global Parkinson’s Disease Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2025
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region

Chapter 10 North America Parkinson’s Disease Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Market Size (US$ Mn) Forecast, by Country, 2017-2025
10.2.1. U.S.
10.2.2. Canada
10.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
10.3.1. Levodopa Combination
10.3.2. Dopamine Agonists
10.3.3. MAO-B Inhibitors
10.3.4. COMT Inhibitors
10.3.5. Others
10.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
10.4.1. Oral
10.4.2. Transdermal
10.4.3. Subcutaneous
10.4.4. Intestinal Infusion
10.4.5. Other
10.5. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Route of Administration
10.6.4. By Distribution Channel

Chapter 11 Europe Parkinson’s Disease Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
11.3.1. Levodopa Combination
11.3.2. Dopamine Agonists
11.3.3. MAO-B Inhibitors
11.3.4. COMT Inhibitors
11.3.5. Others
11.4. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
11.4.1. Oral
11.4.2. Transdermal
11.4.3. Subcutaneous
11.4.4. Intestinal Infusion
11.4.5. Others
11.5. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
11.6.1. By Country
11.6.2. By Drug Class
11.6.3. By Route of Administration
11.6.4. By Distribution Channel

Chapter 12 Asia Pacific Parkinson’s Disease Therapeutics Market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
12.4.1. Levodopa Combination
12.4.2. Dopamine Agonists
12.4.3. MAO-B Inhibitors
12.4.4. COMT Inhibitors
12.4.5. Others
12.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
12.5.1. Oral
12.5.2. Transdermal
12.5.3. Subcutaneous
12.5.4. Intestinal Infusion
12.5.5. Others
12.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
12.7.1. By Country
12.7.2. By Drug Class
12.7.3. By Route of Administration
12.7.4. By Distribution Channel

Chapter 13 Latin America Parkinson’s Disease Therapeutics Market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
13.4.1. Levodopa Combination
13.4.2. Dopamine Agonists
13.4.3. MAO-B Inhibitors
13.4.4. COMT Inhibitors
13.4.5. Others
13.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
13.5.1. Oral
13.5.2. Transdermal
13.5.3. Subcutaneous
13.5.4. Intestinal Infusion
13.5.5. Others
13.6. Market Size (US$ Mn) Forecast by Distribution Channel, 2017-2025
13.6.1. Hospital Pharmacy
13.6.2. Retail Pharmacy
13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
13.7.1. By Country/Sub-region
13.7.2. By Drug Class
13.7.3. By Route of Administration
13.7.4. By Distribution Channel

Chapter 14 Middle East & Africa Parkinson’s Disease Therapeutics Market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2025
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East & Africa
14.4. Market Size (US$ Mn) Forecast, by Drug Class, 2017-2025
14.4.1. Levodopa Combination
14.4.2. Dopamine Agonists
14.4.3. MAO-B Inhibitors
14.4.4. COMT Inhibitors
14.4.5. Others
14.5. Market Size (US$ Mn) Forecast, by Route of Administration, 2017-2025
14.5.1. Oral
14.5.2. Transdermal
14.5.3. Subcutaneous
14.5.4. Intestinal Infusion
14.5.5. Others
14.6. Market Size (US$ Mn) Forecast, by Distribution Channel, 2017-2025
14.6.1. Hospital Pharmacy
14.6.2. Retail Pharmacy
14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
14.7.1. By Country/Sub-region
14.7.2. By Drug Class
14.7.3. By Route of Administration
14.7.4. By Distribution Channel

Chapter 15 Competition Landscape
15.1. Global Parkinson’s Disease Therapeutics Market Share, by Company, 2016
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. AbbVie, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

15.3.2. UCB Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Strategic Overview

15.3.3. Merck & Co., Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.4. Valeant Pharmaceuticals International, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.5. Novartis AG

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.6. Boehringer Ingelheim GmbH.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.7. GlaxoSmithKline plc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.8. Teva Pharmaceutical Industries Ltd.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.9. STADA Arzneimittel AG.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.10. Impax Laboratories, Inc.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

15.3.11. F. Hoffmann-La Roche Ltd.

  • Company Overview (HQ, Business Segments, Employee Strength)
  • Product Portfolio
  • SWOT Analysis
  • Financial Overview
  • Strategic Overview

List of Table

Table 01: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 02: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 03: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 04: Global Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 05: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 06: North America Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 07: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 08: North America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 09: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 10: Europe Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 11: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 12: Europe Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 13: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 14: Asia Pacific Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 15: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 16: Asia Pacific Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 17: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 18: Latin America Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 19: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 20: Latin America Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025
Table 21: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Country, 2015–2025
Table 22: Middle East & Africa  Parkinson's Disease Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
Table 23: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Route of Administration, 2015–2025
Table 24: Middle East & Africa Parkinson's Disease Therapeutics Market Value (US$ Mn) Forecast, by Distribution Channel, 2015–2025

List of Chart

Figure 01: Global Parkinson’s Disease Therapeutics Market Size (US$ Mn) Forecast, 2015–2025
Figure 02: Market Value Share, by Drug Class (2016)
Figure 03: Market Value Share, by Route of Administration (2016)
Figure 04: Market Value Share, by Distribution Channel (2016)
Figure 05: Market Value Share, by Region (2016)
Figure 06: Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Drug Class, 2016 and 2025
Figure 07: Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class, 2017–2025
Figure 08: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Levodopa Combination, 2015–2025
Figure 09: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Dopamine Agonists, 2015–2025
Figure 10: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Monoamine Oxidase B Inhibitors (MAO-B Inhibitors), 2015–2025
Figure 11: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Catechol-O-methyltransferase (COMT) Inhibitors, 2015–2025
Figure 12: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 13: Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Route of Administration, 2016 and 2025
Figure 14: Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration, 2017–2025
Figure 15: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral, 2015–2025
Figure 16: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Transdermal, 2015–2025
Figure 17: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Subcutaneous, 2015–2025
Figure 18: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Intestinal Infusion, 2015–2025
Figure 19: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Others, 2015–2025
Figure 20: Global Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Distribution Channel, 2016 and 2025
Figure 21: Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel, 2017–2025
Figure 22: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
Figure 23: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
Figure 24: Global Parkinson's Disease Therapeutics Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015–2025
Figure 25: Global Parkinson's Disease Therapeutics Market Value Share Analysis, by Region, 2016 and 2025 
Figure 26: Global Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Region, 2017–2025
Figure 27: North America Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 28: North America Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country , 2016 and 2025
Figure 29: North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 30: North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 31: North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 32: North America Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 33: North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 34: North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 35: North America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 36: Europe Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 37: Europe Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
Figure 38: Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 39: Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 40: Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 41: Europe Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 42:  Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 43: Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 44: Europe Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 45: Asia Pacific Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 46: Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
Figure 47: Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 48: Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 49: Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 50: Asia Pacific Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 51: Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 52: Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 53: Asia Pacific Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 54: Latin America Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 55: Latin America Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
Figure 56: Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 57: Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 58: Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 59: Latin America Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 60: Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 61: Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 62: Latin America Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 63: Middle East & Africa Parkinson's Disease Therapeutics Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017–2025
Figure 64: Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis (US$ Mn), by Country, 2016 and 2025
Figure 65: Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Country, 2017–2025
Figure 66: Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2025
Figure 67: Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Route of Administration, 2016 and 2025
Figure 68: Middle East & Africa Parkinson's Disease Therapeutics Market Value Share Analysis, by Distribution Channel, 2016 and 2025
Figure 69: Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Drug Class
Figure 70: Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Route of Administration
Figure 71: Middle East & Africa Parkinson's Disease Therapeutics Market Attractiveness Analysis, by Distribution Channel
Figure 72: Global Parkinson’s Disease Therapeutics Market Share Analysis, by Company (2016)
Figure 73: AbbVie, Inc.’s Breakdown of Net Sales, by Region
Figure 74: AbbVie, Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 75: AbbVie, Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 77: UCB Inc.’s Breakdown of Net Sales, by Therapeutic Area
Figure 79: UCB Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 76: UCB Inc.’s Breakdown of Net Sales, by Region
Figure 78 : UCB Inc.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 79: UCB Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 80: Merck & Co., Inc.’s  Sales Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 81: Merck & Co., Inc.’s  Net Sales Breakdown, by Region, 2016
Figure 82: Merck & Co., Inc.’s Breakdown of Net Sales, by Business Segment, 2016
Figure 83: Merck & Co., Inc.’s Research and Development Expenditure (US$ Mn) and Intensity (%), 2016 and 2015
Figure 84: Valeant Pharmaceuticals International, Inc.’s Breakdown of Net Sales, by Region, 2016
Figure 85: Valeant Pharmaceuticals International, Inc.’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
Figure 86: Valeant Pharmaceuticals International, Inc.’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 87: Novartis AG’s Breakdown of Net Sales, by Region
Figure 88: Novartis AG’s Breakdown of Net Sales, by Business Segment
Figure 89: Novartis AG’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2015–2016
Figure 90: Novartis AG’s R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 91: Boehringer Ingelheim GmbH Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 92: Boehringer Ingelheim GmbH’s Breakdown of Net Sales, by Business and Business Segment Level, 2016
Figure 93: Boehringer Ingelheim GmbH’s Breakdown of Net Sales, by Region (Company Level), 2016
Figure 94: Boehringer Ingelheim GmbH’s R&D Expenditure (US$ Bn), 2013–2016
Figure 95: GSK’s Sales Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2016
Figure 96: GSK’s Breakdown of GSK’s Pharmaceutical’s R&D Expenditure (US$ Bn)
Figure 97: GSK’s Breakdown of GSK’s Net Sales, by Region, 2016
Figure 98: GSK’s Breakdown of GSK’s Net Sales, by Business Segment, 2016
Figure 99: Teva Pharmaceutical Industries Ltd.’s Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 100: Teva Pharmaceutical Industries Ltd.’s R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 101: Teva Pharmaceutical Industries Ltd.’s Breakdown of Net Sales, by Region 2016
Figure 102: Teva Pharmaceutical Industries Ltd.’s Breakdown of Net Sales, (Overall Company Level), 2016
Figure 103: STADA’s Breakdown of Net Sales, by Region, 2016
Figure104: STADA’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
Figure 105: STADA’s Breakdown of Net Sales, by Business Segment Level, 2016
Figure 106: Impax’s Breakdown of Net Sales, by Region, 2016
Figure 107: Impax’s Revenue (US$ Bn) and Y-o-Y Growth (%), 2014–2016
Figure 108: Impax’s Breakdown of Net Sales, by Business Segment Level, 2016
Figure 109: F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 110: F. Hoffmann-La Roche AG Marketing and R&D Expenses, 2015–2016
Figure 111: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division, 2016
Figure 112: F. Hoffmann-La Roche AG Breakdown of Net Sales (Pharmaceutical Segment), by Region, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *